BioAge Labs, Inc.
BIOA
$4.38
$0.153.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 29.72% | -1.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.47% | 62.09% | |||
| Operating Income | -2.47% | -62.09% | |||
| Income Before Tax | 9.73% | -72.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.73% | -72.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.73% | -72.35% | |||
| EBIT | -2.47% | -62.09% | |||
| EBITDA | -2.44% | -62.37% | |||
| EPS Basic | 91.24% | 15.61% | |||
| Normalized Basic EPS | 91.21% | 15.61% | |||
| EPS Diluted | 91.24% | 15.61% | |||
| Normalized Diluted EPS | 91.21% | 15.61% | |||
| Average Basic Shares Outstanding | 930.56% | 104.24% | |||
| Average Diluted Shares Outstanding | 930.56% | 104.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||